#Sweden #Gothenburg #Zinzino #Faun Pharma

Zinzino AB Sees Exceptional Growth in Q3 2025 Sales

Zinzino AB has announced a significant increase in revenue for the third quarter of 2025, showcasing its robust performance across different regional markets. According to the preliminary sales report released on October 3, 2025, the company reported a staggering 53% rise in revenue for its sales markets in September alone, bringing total sales to SEK 273.5 million, up from SEK 178.7 million in the previous year. This impressive growth is indicative of Zinzino's strategic initiatives and market adaptability.

In the broader context, Zinzino saw an overall increase of 50% in revenues amounting to SEK 277.2 million, compared to SEK 184.5 million in the same quarter of the previous year. Such results point to the company's effective sales strategies and product offerings that resonate well with its consumer base.

Regional Breakdown of Sales Growth

The company also provided a detailed breakdown of revenue by region, revealing impressive growth across various markets:

• - The Nordics: Revenue grew by 4%, totaling SEK 79.6 million for Q3 2025.
• - Central Europe: This region experienced astonishing growth of 93%, reaching SEK 242.8 million.
• - East Europe: A modest growth of 4%, amounting to SEK 89.7 million.
• - South West Europe: Revenue surged by 32% to SEK 137.2 million.
• - The Baltics: This area saw a revenue increase of 24%, totaling SEK 28.6 million.
• - North America: Strikingly, North America grew by 103%, culminating in SEK 129.8 million.
• - Asia-Pacific: Revenue in this region skyrocketed by 125%, reaching SEK 63.7 million.
• - Africa: A growth of 58% was recorded, taking revenue to SEK 5.8 million.

The total revenue for Zinzino's sales markets for the third quarter of 2025 reached SEK 777.3 million, a remarkable 54% increase from SEK 504.4 million in Q3 2024. This pattern of growth is not just a reflection of market dynamics but also showcases Zinzino's unwavering commitment to quality and customer satisfaction.

Year-to-Date Performance

When looking at the year-to-date figures from January to September 2025, Zinzino reported a cumulative revenue of SEK 2,304.9 million, translating to a remarkable 54% increase compared to SEK 1,494.3 million in the same period of 2024. This consistent upward trajectory highlights Zinzino's growing footprint in the global market.

Despite seeing a decline in Faun Pharma's external sales, which dropped to SEK 3.7 million from SEK 5.8 million, Zinzino's overall performance remained resilient. The revenue growth across its primary segments underscores the company's ability to navigate challenges while continuing to expand.

Looking Forward

As Zinzino continues to evolve, stakeholders and analysts alike will be keenly observing how the company capitalizes on its current growth momentum. The impressive Q3 performance positions Zinzino favorably for future expansions, particularly in the rapidly growing North American and Asia-Pacific markets. Experts anticipate that continued investment in product innovation and market expansion could further bolster Zinzino's market share and revenue streams in the coming quarters.

In conclusion, Zinzino AB's preliminary sales report for Q3 2025 showcases a remarkable growth trajectory, underpinned by strategic marketing efforts and a diverse product portfolio. The significant increases across multiple regions reflect a company not only on the rise but one poised for a successful future in a competitive landscape.